A placebo-controlled, double-blind Phase 3 study to assess Rocatinlimab in Prurigo nodularis
Zusammenfassung der Studie
This is a Phase III study, the early development phase of drugs for humans. The researchers will examine and provide information on how well Rocatinlimab works and how well it is tolerated compared to placebo in a person for the treatment of PN, and whether it causes side effects. The study may last up to 68 weeks for each participant and includes a pre-screening period of up to 4 weeks, a 52-week treatment period, and a safety follow-up appointment 16 weeks after the last dose of Rocatinlimab. The study will include men and/or women who are at least 18 years old and have PN that has been diagnosed by a doctor at least 3 months prior to signing the informed consent. Participants must have used topical corticosteroids for the daily treatment of PN for at least 14 days (or for the recommended duration of drug use) without a reduction or disappearance of PN symptoms before signing the informed consent. A sufficient period must have elapsed between the previous PN treatment and the study treatment. Participants with other serious illnesses (e.g., cancer, severe depression, certain heart diseases) that are prone to severe allergic reactions or infections, or who have taken or are taking other medications not allowed in the study, are not permitted to participate in the study. Pregnant or breastfeeding participants are not allowed to participate in the study.
(BASEC)
Untersuchte Intervention
Participants will receive either Rocatinlimab (2 different doses) or a placebo as an injection directly under the skin.
Rocatinlimab is a protein-based medication. It has been specifically designed to bind to the OX40 protein on cells involved in inflammatory processes and to interfere with its function.
(BASEC)
Untersuchte Krankheit(en)
Prurigo nodularis – in adult participants whose disease cannot be adequately controlled with topical therapies or who are not suitable for topical therapies.
(BASEC)
- Clinical diagnosis of PN (defined by core symptoms according to the US expert panel consensus [Elmariah et al, 2021]), present for at least 3 months prior to signing the informed consent. - At least ≥ 20 PN nodules at initial screening and on Day 1 prior to randomization with bilateral distribution on both legs and/or both arms and/or the trunk. (BASEC)
Ausschlusskriterien
- Skin or systemic diseases, excluding prurigo nodularis, that have been active or require treatment within the last 3 months and that may affect the evaluation of study outcomes. - Secondary prurigo nodularis due to medications. - Secondary prurigo nodularis due to neurological or psychiatric conditions (e.g., notalgia paresthetica, brachioradial pruritus, neurotic excoriations, obsessive-compulsive disorder, delusional parasitosis). - History of severe immunological reactions (e.g., serum sickness, anaphylaxis, or anaphylactic reaction) to another biologic or an excipient of Rocatinlimab. (BASEC)
Studienstandort
Basel, Bern, Zürich
(BASEC)
Sponsor
AMGEN
(BASEC)
Kontakt für weitere Auskünfte zur Studie
Kontaktperson Schweiz
Prof Dagmar Simon
+41 31 632 22 18
dagmar.simon@clutterinsel.chInselspital Bern Universitaetsklinik fuer Dermatologie
(BASEC)
Wissenschaftliche Auskünfte
nicht verfügbar
Name der bewilligenden Ethikkommission (bei multizentrischen Studien nur die Leitkommission)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Datum der Bewilligung durch die Ethikkommission
03.10.2024
(BASEC)
ICTRP Studien-ID
nicht verfügbar
Offizieller Titel (Genehmigt von der Ethikkommission)
20230053 - A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who are Inadequately Controlled on Topical Therapies (BASEC)
Wissenschaftlicher Titel
nicht verfügbar
Öffentlicher Titel
nicht verfügbar
Untersuchte Krankheit(en)
nicht verfügbar
Untersuchte Intervention
nicht verfügbar
Studientyp
nicht verfügbar
Studiendesign
nicht verfügbar
Ein-/Ausschlusskriterien
nicht verfügbar
nicht verfügbar
Primäre und sekundäre Endpunkte
nicht verfügbar
nicht verfügbar
Registrierungsdatum
nicht verfügbar
Einschluss des ersten Teilnehmers
nicht verfügbar
Sekundäre Sponsoren
nicht verfügbar
Weitere Kontakte
nicht verfügbar
Sekundäre IDs
nicht verfügbar
Angaben zur Verfügbarkeit von individuellen Teilnehmerdaten
nicht verfügbar
Weitere Informationen zur Studie
nicht verfügbar
Ergebnisse der Studie
Zusammenfassung der Ergebnisse
nicht verfügbar
Link zu den Ergebnissen im Primärregister
nicht verfügbar